$AMGN (Amgen Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 61.5%)

Graded daily on value B, growth B, profitability A, momentum B, revisions C-. Sector-relative, identical for every user.

Most active credible voices on $AMGN

@theetftracker (ETF Tracker) — 28 mentions · 67.2K followers
@lamonicabuzz (Paul R. La Monica) — 11 mentions · 47.5K followers
@stockmktnewz (Evan) — 11 mentions · 1.2M followers

Recent headlines featuring $AMGN

2026-10-23: AI Spending Doubts Hit Wall Street: S&P 500 Falls 1.21%, SpaceX Drops More Than 9%

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $AMGN are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

For richer charts and full features, open SpikePanel on desktop.

$AMGN — what investors on X are saying · SpikePanel

$AMGNAmgen Inc. · Drug Manufacturers - General · $244B

$462.44

post+2.4%

Event thread

Key events, in time order

23 items

2026-10-29OtherBull
Amgen Hits All-Time High, Draws Market Attention
Multiple sources confirm Amgen's stock reached an all-time high, reflecting market recognition of recent performance
2026-10-278-K filing
8-K: Item 5.02
D1 +0.7% · since +0.9%

21 earlier events

2026-10-25 → 10-27ProductBull🔥Developing
Amgen's IMDELLTRA Combo Cuts SCLC Death Risk by 58% in Phase III
Q3 earnings approaching; market watches commercial progress
D1 +1.2% · since +1.6%
4 waves of this story
- 2026-10-25 Phase 3 data at ESMO show tarlatamab plus Imfinzi improves OS vs Imfinzi alone
- 2026-10-26 Phase 3 data at ESMO 2026 reinforces survival benefit in hard-to-treat cancer
- 2026-10-26 Pre-market +0.5% as market continues to digest positive Phase III data
- 2026-10-27 Q3 earnings approaching; market watches commercial progress
2026-10-26Company
Amgen Appoints David W. Gibbs to Board of Directors
New independent director may influence strategic decisions
D1 +1.2% · since +1.6%
2026-10-20ProductBull
Tezspire Achieves Histologic Remission and Symptom Improvement in EoE
Week 52 data show statistically significant total endoscopic remission with no visible inflammation or fibrosis
D1 +3.3% · +5d +2.1%
2026-10-20Company
Amgen to Host Investor Webcast at ESMO 2026
Company to hold investor call on Oct 24 during ESMO congress, showcasing pipeline updates
D1 +3.3% · +5d +2.1%
2026-10-08Analyst
Cantor Fitzgerald Raises Amgen PT to $440, Maintains Neutral
Analyst sees core portfolio upside through 2H, flags debate over MariTide data
D1 -1.4% · +5d +6.5%
2026-09-22 → 09-23ProductBull
AMGN Dazodalibep Phase 3 Positive, Jefferies Raises PT to $410
Phase 3 data corroborated by multiple sources; analyst action confirms positive readout
D1 +4.3% · +5d +3.3%
2 waves of this story
- 2026-09-22 Phase 3 success, but approval filing awaits another trial data
- 2026-09-23 Phase 3 data corroborated by multiple sources; analyst action confirms positive readout
2026-09-10ProductBull
AMGN-AZN Combo Shows Survival Benefit in Lung Cancer Study
Imdelltra-Imfinzi combo shows survival benefit in first-line ES-SCLC, broadening market potential
D1 -2.2% · +5d -0.7%
2026-09-10Analyst
HSBC downgrades to Hold
D1 -2.2% · +5d -0.7%
2026-09-09ProductBear
Novartis Lp(a) Drug Phase III Failure Pressures AMGN's Olpasiran
Novartis' pelacarsen misses primary endpoint, raising doubts about AMGN's olpasiran
D1 -0.5% · +5d -3.8%
2026-09-09AnalystBear
BMO Downgrades AMGN to Market Perform
BMO cites LOE headwinds, growth uncertainty, and need for MariTide clarity
D1 -0.5% · +5d -3.8%
2026-09-08Analyst
BMO Capital downgrades to Market Perform
D1 -10.1% · +5d -4.5%
2026-08-31ProductBull
Repatha Cuts Death Risk by 20% in High-Risk Primary Prevention Trial
First PCSK9 inhibitor to show all-cause mortality benefit in primary prevention, potentially strengthening product position
D1 -0.6% · +5d -8.5%
2026-08-27ProductBull
TEZSPIRE Phase 3 Positive in Eosinophilic Esophagitis
Phase 3 met co-primary and key secondary endpoints in EoE, with durable efficacy through Week 52
D1 -0.8% · +5d +1.6%
2026-08-19CapitalBull
AMGN Hits 52-Week High, Multiple Funds Boost Stakes
Cane Capital raised stake 73.2%; shares hit new highs alongside MRK, signaling investor interest
D1 +4.0% · +5d -0.5%
2026-08-05Earnings
Amgen Q2 Revenue Tops $10B, Raises Guidance, Halts Obesity Drug
Multiple sources confirm Q2 beat and raised 2026 outlook despite biosimilar pressure
D1 +4.6% · +5d +2.0%
2 waves of this story
- 2026-08-05 Q2 beat, raises FY revenue and EPS guidance, ends early obesity program
- 2026-08-05 Multiple sources confirm Q2 beat and raised 2026 outlook despite biosimilar pressure
2026-08-04Earnings
Earnings report
D1 +2.9% · +5d +6.2%
2026-07-31 → 08-04CompanyBear
Amgen Discloses Data Breach, Patient Information Stolen
Law firm investigates patient data exposure, ongoing legal action
D1 -0.6% · +5d +6.7%
2 waves of this story
- 2026-07-31 Company filed with SEC, stating hackers stole company data and patient health information from third-party cloud storage systems
- 2026-08-04 Law firm investigates patient data exposure, ongoing legal action
2026-08-04Earnings
Amgen and others to report earnings after tomorrow's close
Multiple sources mention Amgen's earnings timing, market watches results
D1 +2.9% · +5d +6.2%
2026-08-048-K filing
8-K: Item 2.02, Item 9.01
D1 +2.9% · +5d +6.2%
2026-07-318-K filing
8-K: Item 1.05
D1 -0.6% · +5d +6.7%
2026-07-31RegulationBull
European CHMP Supports Broader Use of Repatha® Before First Heart Attack or Stroke
EMA's CHMP issued positive opinion supporting expanded indication for Repatha
D1 -0.6% · +5d +6.7%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

23 items

2026-10-29OtherBull
Amgen Hits All-Time High, Draws Market Attention
Multiple sources confirm Amgen's stock reached an all-time high, reflecting market recognition of recent performance
2026-10-278-K filing
8-K: Item 5.02
D1 +0.7% · since +0.9%
2026-10-25 → 10-27ProductBull🔥Developing
Amgen's IMDELLTRA Combo Cuts SCLC Death Risk by 58% in Phase III
Q3 earnings approaching; market watches commercial progress
D1 +1.2% · since +1.6%
4 waves of this story
- 2026-10-25 Phase 3 data at ESMO show tarlatamab plus Imfinzi improves OS vs Imfinzi alone
- 2026-10-26 Phase 3 data at ESMO 2026 reinforces survival benefit in hard-to-treat cancer
- 2026-10-26 Pre-market +0.5% as market continues to digest positive Phase III data
- 2026-10-27 Q3 earnings approaching; market watches commercial progress
2026-10-26Company
Amgen Appoints David W. Gibbs to Board of Directors
New independent director may influence strategic decisions
D1 +1.2% · since +1.6%
2026-10-20ProductBull
Tezspire Achieves Histologic Remission and Symptom Improvement in EoE
Week 52 data show statistically significant total endoscopic remission with no visible inflammation or fibrosis
D1 +3.3% · +5d +2.1%

18 earlier events

2026-10-20Company
Amgen to Host Investor Webcast at ESMO 2026
Company to hold investor call on Oct 24 during ESMO congress, showcasing pipeline updates
D1 +3.3% · +5d +2.1%
2026-10-08Analyst
Cantor Fitzgerald Raises Amgen PT to $440, Maintains Neutral
Analyst sees core portfolio upside through 2H, flags debate over MariTide data
D1 -1.4% · +5d +6.5%
2026-09-22 → 09-23ProductBull
AMGN Dazodalibep Phase 3 Positive, Jefferies Raises PT to $410
Phase 3 data corroborated by multiple sources; analyst action confirms positive readout
D1 +4.3% · +5d +3.3%
2 waves of this story
- 2026-09-22 Phase 3 success, but approval filing awaits another trial data
- 2026-09-23 Phase 3 data corroborated by multiple sources; analyst action confirms positive readout
2026-09-10ProductBull
AMGN-AZN Combo Shows Survival Benefit in Lung Cancer Study
Imdelltra-Imfinzi combo shows survival benefit in first-line ES-SCLC, broadening market potential
D1 -2.2% · +5d -0.7%
2026-09-10Analyst
HSBC downgrades to Hold
D1 -2.2% · +5d -0.7%
2026-09-09ProductBear
Novartis Lp(a) Drug Phase III Failure Pressures AMGN's Olpasiran
Novartis' pelacarsen misses primary endpoint, raising doubts about AMGN's olpasiran
D1 -0.5% · +5d -3.8%
2026-09-09AnalystBear
BMO Downgrades AMGN to Market Perform
BMO cites LOE headwinds, growth uncertainty, and need for MariTide clarity
D1 -0.5% · +5d -3.8%
2026-09-08Analyst
BMO Capital downgrades to Market Perform
D1 -10.1% · +5d -4.5%
2026-08-31ProductBull
Repatha Cuts Death Risk by 20% in High-Risk Primary Prevention Trial
First PCSK9 inhibitor to show all-cause mortality benefit in primary prevention, potentially strengthening product position
D1 -0.6% · +5d -8.5%
2026-08-27ProductBull
TEZSPIRE Phase 3 Positive in Eosinophilic Esophagitis
Phase 3 met co-primary and key secondary endpoints in EoE, with durable efficacy through Week 52
D1 -0.8% · +5d +1.6%
2026-08-19CapitalBull
AMGN Hits 52-Week High, Multiple Funds Boost Stakes
Cane Capital raised stake 73.2%; shares hit new highs alongside MRK, signaling investor interest
D1 +4.0% · +5d -0.5%
2026-08-05Earnings
Amgen Q2 Revenue Tops $10B, Raises Guidance, Halts Obesity Drug
Multiple sources confirm Q2 beat and raised 2026 outlook despite biosimilar pressure
D1 +4.6% · +5d +2.0%
2 waves of this story
- 2026-08-05 Q2 beat, raises FY revenue and EPS guidance, ends early obesity program
- 2026-08-05 Multiple sources confirm Q2 beat and raised 2026 outlook despite biosimilar pressure
2026-08-04Earnings
Earnings report
D1 +2.9% · +5d +6.2%
2026-07-31 → 08-04CompanyBear
Amgen Discloses Data Breach, Patient Information Stolen
Law firm investigates patient data exposure, ongoing legal action
D1 -0.6% · +5d +6.7%
2 waves of this story
- 2026-07-31 Company filed with SEC, stating hackers stole company data and patient health information from third-party cloud storage systems
- 2026-08-04 Law firm investigates patient data exposure, ongoing legal action
2026-08-04Earnings
Amgen and others to report earnings after tomorrow's close
Multiple sources mention Amgen's earnings timing, market watches results
D1 +2.9% · +5d +6.2%
2026-08-048-K filing
8-K: Item 2.02, Item 9.01
D1 +2.9% · +5d +6.2%
2026-07-318-K filing
8-K: Item 1.05
D1 -0.6% · +5d +6.7%
2026-07-31RegulationBull
European CHMP Supports Broader Use of Repatha® Before First Heart Attack or Stroke
EMA's CHMP issued positive opinion supporting expanded indication for Repatha
D1 -0.6% · +5d +6.7%

$AMGN (Amgen Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 61.5%)

Most active credible voices on $AMGN

Recent headlines featuring $AMGN

$AMGN (Amgen Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 61.5%)

Most active credible voices on $AMGN

Recent headlines featuring $AMGN

Amgen Hits All-Time High, Draws Market Attention

8-K: Item 5.02

Amgen's IMDELLTRA Combo Cuts SCLC Death Risk by 58% in Phase III

Amgen Appoints David W. Gibbs to Board of Directors

Tezspire Achieves Histologic Remission and Symptom Improvement in EoE

Amgen to Host Investor Webcast at ESMO 2026

Cantor Fitzgerald Raises Amgen PT to $440, Maintains Neutral

AMGN Dazodalibep Phase 3 Positive, Jefferies Raises PT to $410

AMGN-AZN Combo Shows Survival Benefit in Lung Cancer Study

HSBC downgrades to Hold

Novartis Lp(a) Drug Phase III Failure Pressures AMGN's Olpasiran

BMO Downgrades AMGN to Market Perform

BMO Capital downgrades to Market Perform

Repatha Cuts Death Risk by 20% in High-Risk Primary Prevention Trial

TEZSPIRE Phase 3 Positive in Eosinophilic Esophagitis

AMGN Hits 52-Week High, Multiple Funds Boost Stakes

Amgen Q2 Revenue Tops $10B, Raises Guidance, Halts Obesity Drug

Earnings report

Amgen Discloses Data Breach, Patient Information Stolen

Amgen and others to report earnings after tomorrow's close

8-K: Item 2.02, Item 9.01

8-K: Item 1.05

European CHMP Supports Broader Use of Repatha® Before First Heart Attack or Stroke

Bull vs bear

Discussion

Amgen Hits All-Time High, Draws Market Attention

8-K: Item 5.02

Amgen's IMDELLTRA Combo Cuts SCLC Death Risk by 58% in Phase III

Amgen Appoints David W. Gibbs to Board of Directors

Tezspire Achieves Histologic Remission and Symptom Improvement in EoE

Amgen to Host Investor Webcast at ESMO 2026

Cantor Fitzgerald Raises Amgen PT to $440, Maintains Neutral

AMGN Dazodalibep Phase 3 Positive, Jefferies Raises PT to $410

AMGN-AZN Combo Shows Survival Benefit in Lung Cancer Study

HSBC downgrades to Hold

Novartis Lp(a) Drug Phase III Failure Pressures AMGN's Olpasiran

BMO Downgrades AMGN to Market Perform

BMO Capital downgrades to Market Perform

Repatha Cuts Death Risk by 20% in High-Risk Primary Prevention Trial

TEZSPIRE Phase 3 Positive in Eosinophilic Esophagitis

AMGN Hits 52-Week High, Multiple Funds Boost Stakes

Amgen Q2 Revenue Tops $10B, Raises Guidance, Halts Obesity Drug

Earnings report

Amgen Discloses Data Breach, Patient Information Stolen

Amgen and others to report earnings after tomorrow's close

8-K: Item 2.02, Item 9.01

8-K: Item 1.05

European CHMP Supports Broader Use of Repatha® Before First Heart Attack or Stroke